Impact of administrative restrictions on antibiotic use and expenditure in Ontario: Time series analysis

Journal of Health Services Research and Policy

Volumn 11, Issue 1, 2006, Pages 13-20

  Marshall, Deborah ^a   Gough, Jacqueline ^a   Grootendorst, Paul ^b   Buitendyk, Melanie ^a   Jaszewski, Barbara ^c   Simonyi, Susan ^a   Jivraj, Farah ^c   MacLeod, Stuart ^d  

^a i3 Global   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Bayer HealthCare Inc   (Canada)

^d CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; LEVOFLOXACIN; MACROLIDE; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CANADA; DRUG COST; DRUG HYPERSENSITIVITY; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RISK BENEFIT ANALYSIS;

AGED; ANTI-BACTERIAL AGENTS; COST CONTROL; HEALTH EXPENDITURES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; NATIONAL HEALTH PROGRAMS; ONTARIO; PHYSICIAN'S PRACTICE PATTERNS; POLICY MAKING; REIMBURSEMENT MECHANISMS;

EID: 30944464969     PISSN: 13558196     EISSN: None     Source Type: Journal    
DOI: 10.1002/ar.a.20273     Document Type: Article

References (26)

1. Levine MA, Pradhan A. Can the health care system buy better antibiotic prescribing behaviour? CMAJ 1999;160:1023
2. Low DE. Antimicrobial drug use and resistance among respiratory pathogens in the community. Clin Infect Dis 2001;33(Suppl. 3):S206
3. Blasi F, Tarsia P, Cosentini R, et al. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. Expert Opin Invest Drug 2003;12:1165
4. Drug Quality and Therapeutic Committee. Antibiotic resistance: antibiotic review and Ontario Drug Benefit formulary listing changes. DQTC Bull February 2001
5. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233
6. Burke JP. Antibiotic resistance - squeezing the balloon? JAMA 1998;280:1270
7. Ministry of Health and Long-Term Care. 2001/02 Report Card for Ontario Drug Benefit Program. Toronto, 2002
8. The DELTA Report Summary of Findings. DELTA: Drug Expenditure Longitudinal Trend Analysis 2000
9. Ostrom CW. Time Series Analysis: Regression Techniques. Newbury Park, CA: Sage, 1990
10. Brocklebank JC, Dickey DA. SAS System for Forecasting Time Series. Cary, NC: SAS Institute, 1986
11. McDowall D, McCleary R, Meidinger EE, Hay RA. Interrupted Time Series Analysis. Thousand Oaks, CA: Sage, 1980. Sage University series on Quantitative Applications in the Social Sciences, series no. 07-021
12. Box GEP, Jenkins GM. Time Series Analysis: Forecasting and Control. Oakland, CA: Holden-Day, 1976
13. SAS Institute. Introduction to Time Series Forecasting Using SAS Software: Course Notes. Cary, NC: SAS Institute, 2000
14. Greenland S, Rothman KJ. Fundamentals of Epidemiologic Data Analysis. In: Rothman KJ and Greenland S, eds. Modern Epidemiology, Chapter 13. Philadelphia, PA: Lippincott William & Wilkins, 1998, p. 201
15. Kurzer E, Kaplan S. Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. Eur Urol 2002;42:163
16. Fisher MA, Schneeweiss S, Avorn J, et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004;351:2187
17. LeLorier J, Derderian F. Effect of listing ciprofloxacin in provincial formularies on hospitalizations for bronchitis and pyelonephritis. Can J Clin Pharmacol 1998;5:133
18. Beilby J, Marley J, Walker D, et al. Effect of changes in antibiotic prescribing on patient outcomes in a community setting: a natural experiment in Australia. Clin Infect Dis 2002;34:55
19. Birnbaum D, Jandciu E, Twells L. Antimicrobial resistance: a deadly burden no country can afford to ignore. Vancouver: Canadian Committee on Antibiotic Resistance, 2002
20. Controlling antimicrobial resistance. An integrated action plan for Canadians. Can Commun Dis Rep 1997;23(Suppl. 7):i
21. Canadian Committee on Antibiotic Resistance (CCAR). Controlling antimicrobial resistance in Canada - strategies, perspectives, programs. Can J Infect Dis 2003;11:1C
22. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999;43:459
23. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441
24. Westh H, Jarlov JO, Kjersem H, et al. The disappearance of multiresistant Staphylococcus aureus in Denmark: changes in strains of the 83A complex between 1969 and 1989. Clin Infect Dis 1992;14:1186
25. Zhanel GG, Karlowsky JA, Low DE, et al. Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998. J Antimicrob Chemother 2000;45:655
26. Metge CJ, Vercaigne L, Carrie AG, et al. New Fluoroquinolones in Community-Acquired Pneumonia: A Clinical and Economic Evaluation. Technology Report Technology Report, 2001;1